Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients

Expert Opinion on Drug Safety

Volumn 9, Issue 3, 2010, Pages 431-445

  Vigan, Alessandra ^a   Cerini, Chiara ^a   Pattarino, Giulia ^a   Fasan, Silvia ^a   Zuccotti, Gian Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiretroviral therapy; Children; Dyslipidaemia; Hyperlactataemia syndromes; Insulin resistance; Lipodystrophy; Metabolic complications; Mitochondrial toxicity

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BIGUANIDE DERIVATIVE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EZETIMIBE; GLITAZONE DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INSULIN; LACTIC ACID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; NELFINAVIR; NEVIRAPINE; ORAL ANTIDIABETIC AGENT; RECOMBINANT GROWTH HORMONE; RESIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ABDOMINAL CRAMP; ANEMIA; BLOATING; BODY FAT DISTRIBUTION; BRAIN DISEASE; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; EXERCISE; FATTY LIVER; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; HYPERLACTATEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN TREATMENT; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIVER DYSFUNCTION; LIVER FAILURE; LIVER INJURY; METABOLIC DISORDER; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREATITIS; PATIENT COMPLIANCE; PRENATAL EXPOSURE; PSYCHOMOTOR DISORDER; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; TERATOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; VISUAL DISORDER; WEIGHT GAIN;

ANIMALS; ANTI-HIV AGENTS; CHILD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; METABOLIC DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 77951644312     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903579991     Document Type: Review

References (126)

1. Gortmaker S, Hughes M, Cervia J, et al. Effects of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345(21):1522-1528
2. De martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registy. JAMA 2000;248(2):190-197
3. Chiappini E, Galli L, Tovo PA, et al. Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian Register for HIV Infection in Children. J Clin Oncol 2007;25(1):97-101
4. Nachman SA, Lindsey JC, Moyle J, et al. Groeth of human immunodeficiency virus infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005;24(4):352-357
5. Chiriboga CA, Fleishman S, Champions S, et al. Incidence and prevalence of HIV encelopathy in children with HIV infection receiving highly active antiretroviral therapy (HAART). J Pediatr 2005;146(3):402-407
6. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus infected children. Pediatr Infect Dis J 2003(10):863-867
7. Cooper ER, Charurat M, Mofenson LM, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol 2002;29(5):484-494
8. Kohler J, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ mol Mutagen 2007; 48:166-172
9. Gerschenson M, Poirier MC. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann NY Acad Sci 2000;918:269-281
10. Bialkowska A, Bialkowski K, Gerschenson M, et al. Oxidative DNA damage in fetal tissues after transplacental exposure to 3'-azido-3'-deoxythymidine (AZT). Carcinogenesis 2000;21:1059-1062
11. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004;114(5):e598-603
12. Giaquinto C, Romeo AD, Giacomet V, et al. Lacitc acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001;15:1074-1075
13. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic academia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003;22:782-788
14. Giaquinto C, Rampon O, Torresan S, et al. Lactic acid levels in infant exposed to antiretrovirals durino fetal life [abstract 941]. 11th Conference on retroviruses and opportunistic infections; 2004; San Francisco, USA
15. Ekouevi DK, Tourè R, Becquet R, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother to child transmission of HIV: Agence Nationale de Reserches sur le SIDA et les Hépatites virales 1209 Study, Abidijan, Ivory Coast. Pediatrics 2006;118:e1071-7
16. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-1089 (Pubitemid 29452821)
17. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunctions in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769-1785
18. Tovo PA, Chiappello N, Gabiano C, et al. Zidovudine alteration during pregnancy and mitochondrial disease in the offspring. Antivir Ther 2005;10:697-699
19. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in 5 United States cohorts. J AIDS 2000;25:261-268
20. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J AIDS 2003;32:380-387
21. Lindegren ML, Rhodes P, Gordon L, et al. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in paediatric HIV surveillance. Ann NY Acad Sci 2000;918:222-235
22. Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offsprings of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann NY Acad Sci 2000;918:212-221
23. Imhof A, Ledergerber B, Güthard HF, et al. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin Infec Dis 2005;41(5):721-728
24. Calza L, Manfredi R. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 2005;24(1):5-15
25. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-846
26. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15(6):795-797
27. Noguera A, Fortuny C, Sanchez E, et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J 2003;22:778-782
28. Desai N, Mathur M, Weedon J, et al. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003;17:1565-1568
29. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000;133:192-196
30. Church JA, Mitchell WG, Gonzalez-Gomez I, et al. Mithocondrial DNA depletion, near-fatal metabolic acidosis and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 2001;138:738-741
31. Rey C, Prieto S, Medina A, et al. Fatal lactic acidosis during antiretroviral therapy. Pediatr Crit Care Med 2003;4:485-487
32. Guidelines for the use of Antiretroviral Agents in Pediatric HIV Infection. Developed by the Working Group on Antiretroviral Theraphy and Medical Management of HIV-infected Children. Supplement III: Pediatric Adverse Drug Events. 28 February 2008
33. Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab 2008;93:2937-2945
34. Cofrancesco J, Freedland E, McComsey G. Treatment options for HIV-Associated central fat accumulation. AIDS Patient Care 2009;23(1):5-18
35. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46(4):451-455
36. Leonard EG, McComsey GA. Metabolic complication of antiretroviral therapy in children. Pediatr Infect Dis J 2003;22:77-84
37. European Pediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and Hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-1451
38. Taylor P, Worrel C, Stainberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long term protease inhibitor-containing, highly active antiretroviral regimens. Pediatrics 2004;114e:235-242
39. McComsey GA, Leonard E. Metabolic complications of HIV-therapy in children. AIDS 2004;3(18):1753-1768
40. Babl FE, Regan AM, Peltron SI. Abnormal body-fat distribution in HIV-infected children on antiretrovirals. Lancet 1999;353:1243-1244
41. Bockhorst Jl, Ksseiry I, Toye M. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Peditr Infect Dis J 2003;22:463-465
42. Ene L, Goetghebuer T, Hainaut M, et al. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007;166:13-21
43. Jaquet D, Lévine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123-2128
44. Hartman K, Verweel G, De Grut R, et al. Detection of lipoatrophy in immundeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:427-431
45. Thorne C, Goetghebuer T, Viganò A. European Paediatric HIV and Lipodystrophy Study Group. Active surveillance of body fat changes and metabolic abnormalities in HIV-infected children and adolescents in Europe: first round results [abstract 915]. 16th Conference on retroviruses and opportunistic infections; 2009; Montreal, Canada
46. Aurpibul L, Puthanakit T, Lee B, et al. Lipodystrophy and mertabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 2007;12:1247-1254
47. Fredricks AM, Van Buren S, Fekkes M, et al. Are age references for waist circumference, hip circumference and waist hip-ratio in Dutch children useful in clinical practice? Eur J Paediatr 2005;164:216-222
48. Janssen I. Body mass index, waist circumference, and health risk: evidence in support of current national institutes of health guidelines. Arch Intern Med 2002;162:2074-2079
49. Fernandez JR, Redden DT, Pietrobelli A. Waist circumference percentiles in nationally representative sample of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 2004;145:439-444
50. Sempè M, Pedron O, Roy-Pernot MP. Auxologie methodes et sequences. Theràplix, Paris; 1979. p. 138-162
51. Brambilla P, Bricalli D, Sala N, et al. Highly active antiretroviral-treated HIV-infected children showed fat distribution changes even in absence of lipodystrophy. AIDS 2001;15:2415-2422
52. Paton NI, Yang Y, Tha NO, et al. Changes in facial fat in HIV-related lipoatrophy, waisting, and weight gain measured by magnetic resonance imaging. HIV Clin Trials 2007;8:227-234
53. Scherzer R, Shen W, Bacchetti P, et al. Comparison of dual energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected a control subjects. Am J Clin Nutr 2008;88:1088-1096
54. Viganò A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increase exposure to highly active antiretroviral therapy in HIV-infected children. J AIDS 2003;32:482-489
55. Torres AMS, Munitz RM, Madero R, et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005;164:271-276
56. Resino S, Micheloud D, Larrù B, et al. Immunological recovery and metabolic disorders in severe immunodeficiency HIV type-1-infected children on highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1477-1484
57. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005;40(2):161-168
58. Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005;18:25-33
59. Haubrich R, Riddler S, DiRienzo A, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-1118
60. Cooper DA. Altair Study Group. Safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection: week 48 data from a randomized, open-label study. IAS 2009, poster LBPEB09
61. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004;38:263-270
62. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002;288:207-215
63. Fisher M, Moyle G, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Defic Syndr 2009;51:562-568
64. Cavalcanti RB, Raboud J, Shen S, et al. A randomized placebo-controlled trial of rosiglitazone for HIV-realted lipoatrophy. J Infect Dis 2007;195:1754-1761
65. Sutinen J, Walker WUA, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007;12:97-105
66. Mallon PWG, Miliar J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in men-a randomized, placebo-controlled study. AIDS 2006;20:1003-1010
67. Tsiodars S, Poulia KA, Yannakoulia M, et al. Adherence to mediterranean diet is favourably associated with metabolic parameters in HIV positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. J Metab 2009;58:854-859
68. Kotler DP, Muurahainen N, Grumfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patient. J AIDS 2004;35:239-252
69. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-realising factor in patient with HIV. N Engl J Med 2007;357:2349-2370
70. Viganò A, Brambilla P, Cafarelli L, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children. Switch from stavudine to tenofovir and protease inhibitor to efavirenz. Antivir Ther 2007;12:297-302
71. Gonzalez-Tome MI, Ramos Amador Jt, Mellado Pen?a J, et al. Outcome of protease inhibitor substitution with nevirapine in HIV-1-infected children. BMC Infect Dis 2008;22:144
72. Dollfus C, Blanche S, Trocme N, et al. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med 2009;10:263-268
73. Viganò A, Mora S, Manzoni P, et al. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in Human Immunodeficiency Virus-infected adolescents. J Clin Endocr Metab 2005;90:4075-4080
74. Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics 2005;116(2):473-480
75. Rosenbloom AL, Silverstein JH, Amemiya S, et al. Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2009;10(Suppl 12):17-32
76. Borai A, Livingstone C, Ferns GAA. The biochemical assessment of insulin resistance. Ann Clin Biochem 2007;44:324-342
77. Yeckel CW, Weiss R, Dziura J, et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004;89:1096-1101
78. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000;31:1467-1475
79. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254
80. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-1818
81. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43
82. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-18
83. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake-and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006;20(14):1813-1821
84. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS 1998;12:F51-8
85. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099
86. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-139
87. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-2056
88. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165:1179-1184 (Pubitemid 40720744)
89. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care 2008;31(6):1224-1229
90. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005;19:1375-1383
91. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007;21:1739-1745
92. Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005;5:255-262
93. Melvin AJ, Lennon S, Mohan KM, Purnell JQ. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001;17:1117-1123
94. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002;110:e56
95. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003;17:1319-1327
96. Bitnun A, Sochett E, Dick PT, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and-naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005;90:168-174
97. Rosso R, Parodi A, d'Annunzio G, et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol 2007;157(5):655-659
98. Viganò A, Brambilla P, Pattarino G, et al. Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. Clin Drug Investig 2009;29(2):101-109
99. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001;50(11):2444-2450
100. Weiss R, Caprio S. Obesity and T2DM in youth. Endocr Res 2008;33(1-2):59-72
101. Lee B, Aurpibul L, Sirisanthana V, et al. Low prevalence of insulin resistance among HIV-infected children receiving non nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. HIV Med 2009;10(2):72-78
102. Chantry CJ, Hughes MD, Alvero C, et al.; PACTG 1010 Team. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 2008;122(1):e129-38
103. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother 2008;61(2):238-245
104. Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008;49(Suppl 2):S86-92
105. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91:2074-2080
106. Guffanti M, Caumo A, Galli L, et al. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol 2007;156(4):503-509
107. Dubè MP, Stein JH, Abert JA, et al. Guidelines for evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendation of the HIV Medical Association of the Infectious disease Society of America and the Adult AIDS Clinical trials Group. Clin Infect Dis 2003;37:613-627
108. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral theraphy in HIV-infected patients. J Antimicrob Chemother 2003;53:10-14
109. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189(6):1056-1074
110. Newman WP III, Freedman DS, Woors AV, et al. Relation of serum lipoprotein level and sistolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med 1986;314(3):138-144
111. NCEP Export Panel on Blood Cholesterol Levels in Children and Adolescents. National Cholesterol Education Program (NCEP): Highlights of the Report of the Export Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:495-501
112. Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation 2006;114:1056-1062
113. European Pediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-1451
114. Periard D, Talenti A, Sudre P, et al. Marked dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation 1999;100:700-705
115. Cheseaux JI, Jotterand V, Aebi C, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevances for cardiovascular diseases. J Acquire Immune Defic Syndr 2002;30:288-293
116. Farley J, Gona P, Crain M, et al. prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in paediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr 2005;38:480-487
117. Tassiopoulos K, Williams P, Seage G, et al.; for the International Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team. Epidemiology and social science association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J AIDS 2008;47(5):607-614
118. Aldovrandi GM, Lindsey JC, Jacobson D, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23:661-672
119. Rhoads MP, Smith CJ, Tudor-williams G, et al. Effects of higly active antiretroviral therapy on paediatric metabolic levels. HIV Med 2006;7:16-24
120. Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am 2009;38(1):207-222
121. National Cholesterol Education Program. Third report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2008 Available from: http://www.nhlbi.nih.gov/ guidelines/cholesterol/atp3-rtp.htm. [Accessed 23 May 2008]
122. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008;9(2):72-81
123. Karvey RE, Allanda V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; Council of Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research-endorsed by the American Academy of Pediatrics. Circulation 2006;114(24):2710-2738
124. Daniels SR, Gree FR, and the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122(1):198-208
125. McComsey GA, Bhumbra N, Maa J, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics 2003;111(3):e275-81
126. Viganò A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther 2005;10:917-924